期刊文献+
共找到1,588篇文章
< 1 2 80 >
每页显示 20 50 100
Sonodynamic therapy for the treatment of atherosclerosis 被引量:1
1
作者 Yan Zhang Ying Yang +7 位作者 Yudi Feng Xueyan Gao Liping Pei Xiaopan Li Bingxin Gao Lin Liu Chengzeng Wang Shuochen Gao 《Journal of Pharmaceutical Analysis》 SCIE CAS CSCD 2024年第5期666-677,共12页
Atherosclerosis(AS)is a chronic inflammatory disease of large and medium-sized arteries that leads to ischemic heart disease,stroke,and peripheral vascular disease.Despite the current treatments,mortality and disabili... Atherosclerosis(AS)is a chronic inflammatory disease of large and medium-sized arteries that leads to ischemic heart disease,stroke,and peripheral vascular disease.Despite the current treatments,mortality and disability still remain high.Sonodynamic therapy(SDT),a non-invasive and localized methodology,has been developed as a promising new treatment for inhibiting atherosclerotic progression and stabilizing plaques.Promising progress has been made through cell and animal assays,as well as clinical trials.For example,the effect of SDT on apoptosis and autophagy of cells in AS,especially macrophages,and the concept of non-lethal SDT has also been proposed.In this review,we summarize the ultrasonic parameters and known sonosensitizers utilized in SDT for AS;we elaborate on SDT's therapeutic effects and mechanisms in terms of macrophages,T lymphocytes,neovascularization,smooth muscle cells,lipid,extracellular matrix and efferocytosis within plaques;additionally,we discuss the safety of SDT.A comprehensive summary of the confirmed effects of SDT on AS is conducted to establish a framework for future researchers. 展开更多
关键词 atherosclerosis Sonodynamic therapy Sonosensitizer ULTRASOUND Reactive oxygen species
在线阅读 下载PDF
Integrative cardiovascular disease therapy: Linoleic acid restriction, enhanced external counterpulsation, and emerging nanotherapies
2
作者 Joseph Mercola 《World Journal of Cardiology》 2025年第8期38-55,共18页
Cardiovascular disease remains the leading global cause of mortality,projected to increase by 73.4%from 2025 to 2050 despite declining age-standardized rates.Contemporary interventions,such as percutaneous coronary in... Cardiovascular disease remains the leading global cause of mortality,projected to increase by 73.4%from 2025 to 2050 despite declining age-standardized rates.Contemporary interventions,such as percutaneous coronary intervention and statins,reduce major adverse cardiovascular events(MACE)by 25%-30%,yet a 20%five-year MACE risk persists in high-risk cohorts.These approaches,histor-ically focused on luminal stenosis,fail to address systemic atherogenesis drivers like endothelial dysfunction and inflammation.Specifically,dietary linoleic acid restriction(<5 g/day)reduces oxidized low-density lipoprotein by approximately 15%by limiting peroxidation-prone bisallylic bonds,mitigating arterial inflam-mation,a key atherogenic trigger.Enhanced external counterpulsation,through pulsatile shear stress,enhances nitric oxide-mediated coronary perfusion,alle-viating angina in approximately 70%of refractory cases unresponsive to revascu-larization.Nanoparticle-facilitated chelation targets atherosclerotic plaques with precision,reducing calcium content by up to 30%in preclinical models,offering a novel avenue for lesion reversal.These innovations collectively address residual risk by tackling root causes,oxidative stress,endothelial dysfunction,and plaque instability,potentially halving MACE rates with widespread adoption.Despite promising preliminary data,gaps remain in long-term safety and scalability.Robust clinical trials are needed to validate these approaches,which collectively aim to transform cardiovascular disease management by prioritizing prevention and vascular restoration,potentially reducing coronary events to a public health rarity. 展开更多
关键词 Cardiovascular disease atherosclerosis Integrative therapy Linoleic acid reduction Enhanced external counterpulsation Nanoparticle-facilitated chelation Metabolic optimization Residual cardiovascular risk
暂未订购
Hepatocyte growth factor enhances the ability of dental pulp stem cells to ameliorate atherosclerosis in apolipoprotein E-knockout mice 被引量:1
3
作者 Han Duan Ning Tao +8 位作者 Lin Lv Kai-Xin Yan Yong-Gang You Zhuang Mao Chang-Yao Wang Xue Li Jia-Yan Jin Chu-Tse Wu Hua Wang 《World Journal of Stem Cells》 SCIE 2024年第5期575-590,共16页
BACKGROUND Atherosclerosis(AS),a chronic inflammatory disease of blood vessels,is a major contributor to cardiovascular disease.Dental pulp stem cells(DPSCs)are capable of exerting immunomodulatory and anti-inflammato... BACKGROUND Atherosclerosis(AS),a chronic inflammatory disease of blood vessels,is a major contributor to cardiovascular disease.Dental pulp stem cells(DPSCs)are capable of exerting immunomodulatory and anti-inflammatory effects by secreting cytokines and exosomes and are widely used to treat autoimmune and inflam-mation-related diseases.Hepatocyte growth factor(HGF)is a pleiotropic cytokine that plays a key role in many inflammatory and autoimmune diseases.AIM To modify DPSCs with HGF(DPSC-HGF)and evaluate the therapeutic effect of DPSC-HGF on AS using an apolipoprotein E-knockout(ApoE-/-)mouse model and an in vitro cellular model.METHODS ApoE-/-mice were fed with a high-fat diet(HFD)for 12 wk and injected with DPSC-HGF or Ad-Null modified DPSCs(DPSC-Null)through tail vein at weeks 4,7,and 11,respectively,and the therapeutic efficacy and mechanisms were analyzed by histopathology,flow cytometry,lipid and glucose measurements,real-time reverse transcription polymerase chain reaction(RT-PCR),and enzyme-linked immunosorbent assay at the different time points of the experiment.An in vitro inflammatory cell model was established by using RAW264.7 cells and human aortic endothelial cells(HAOECs),and indirect co-cultured with supernatant of DPSC-Null(DPSC-Null-CM)or DPSC-HGF-CM,and the effect and mechanisms were analyzed by flow cytometry,RT-PCR and western blot.Nuclear factor-κB(NF-κB)activators and inhibitors were also used to validate the related signaling pathways.RESULTS DPSC-Null and DPSC-HGF treatments decreased the area of atherosclerotic plaques and reduced the expression of inflammatory factors,and the percentage of macrophages in the aorta,and DPSC-HGF treatment had more pronounced effects.DPSCs treatment had no effect on serum lipoprotein levels.The FACS results showed that DPSCs treatment reduced the percentages of monocytes,neutrophils,and M1 macrophages in the peripheral blood and spleen.DPSC-Null-CM and DPSC-HGF-CM reduced adhesion molecule expression in tumor necrosis factor-αstimulated HAOECs and regulated M1 polarization and inflammatory factor expression in lipopolysaccharide-induced RAW264.7 cells by inhibiting the NF-κB signaling pathway.CONCLUSION This study suggested that DPSC-HGF could more effectively ameliorate AS in ApoE-/-mice on a HFD,and could be of greater value in stem cell-based treatments for AS. 展开更多
关键词 atherosclerosis Apolipoprotein E-knockout mice Cell therapy Dental pulp stem cells Hepatocyte growth factor
暂未订购
The application value of TCD combined with CDUS in the large artery atherosclerosis
4
作者 Shaobin Wang Dong Wang Weixing Huang 《Discussion of Clinical Cases》 2015年第2期1-7,共7页
Objective:To explore the value of TCD and CDUS on diagnosis of large artery atherosclerosis.Methods:In our study,90 patients who had been admitted to our hospital and diagnosed as LAA according to CISS typing were sel... Objective:To explore the value of TCD and CDUS on diagnosis of large artery atherosclerosis.Methods:In our study,90 patients who had been admitted to our hospital and diagnosed as LAA according to CISS typing were selected as the research object.A retrospective analysis was conducted,using CTA as golden standard for diagnoses of stenoses.Explore the risk factors of LAA,the reliability of TCD and CDUS in diagnosis of the stenosis and distribution of stenosis in each vessel.Results:Hypertension and type 2 diabetes are risk factors of LAA vascular stenosis.Middle cerebral artery stenosis detection by TCD carries the highest reliability(sensitivity 90.91%,specificity 97.89%,positive predictive value 96.15%,the negative predictive value was 94.9%,the positive likelihood ratio was 43.18,negative likelihood ratio 0.09,Kappa=0.9).The consistency of TCD is as good as CTA in head and neck part.The negative coincidence rate was higher in the anterior circulation vessels(97.98%),followed by the coincidence rate of severe stenosis(95.23%).However,the detection rate of posterior circulation vessels positive,moderate and severe stenosis,mild stenosis gradually decreased by TCD.CDUS carries general reliability in detecting intracranial extracranial stenosis,the highest reliability in internal carotid artery(kappa 0.82),and the worst consistency in vertebral artery(kappa 0.38).The negative coincidence rate of CDUS in extracranial cerebrovascular stenosis was highest(97.22),followed by the overall compliance rate(91.55%).242 branches of vascular stenosis were discovered in our study,among which intracranial artery stenosis 61.15%(148/242)is higher than that in extracranial artery 38.85%(90/242),ratio of moderate to severe stenosis is as high as 82.23%(199/242).Intracranial artery stenosis in ICA is extremely common(51.11%,46/90),and MCA is the common area of intracranial artery stenosis(37.16%,55/148).Conclusions:(1)Hypertension,type 2 diabetes are risk factors for LAA stenosis.(2)TCD detection of intracranial vascular stenosis carries the best consistency,and reliability of MCA is the highest.In our search,MCA possesses the highest rate of stenosis,and negative coincidence rate by TCD examination was the highest,which could be used for screening method for stenosis.The reliability of TCD in diagnosis of moderate and severe stenosis was relatively better than mild stenosis.(3)CDUS detection of anterior circulation lesions is better than that of posterior circulation lesions.Evaluate effect on moderate and severe stenosis was better than that of mild one.The ratio of ICA stenosis was the highest,but the effect on VA was poor.(4)The incidence of intracranial vascular stenosis is more common than that of the intracranial vascular stenosis. 展开更多
关键词 tcd CDUS Large artery atherosclerosis
暂未订购
Recent advances in targeted stimuli-responsive nano-based drug delivery systems combating atherosclerosis 被引量:3
5
作者 Yilin Song Huaqing Jing +2 位作者 Long Binh Vong Jinping Wang Nan Li 《Chinese Chemical Letters》 SCIE CAS CSCD 2022年第4期1705-1717,共13页
Atherosclerosis(AS), mainly caused by the changed immune system functions and inflammation, is the central pathogenesis of cardiovascular disease, which is a leading cause of death in the world. In modern medicine, th... Atherosclerosis(AS), mainly caused by the changed immune system functions and inflammation, is the central pathogenesis of cardiovascular disease, which is a leading cause of death in the world. In modern medicine, the development of carriers precisely delivering the therapeutic agents to the target sites is the primary goal, which could minimize the potential adverse effects and be more effective in treating lesions. Due to the precise location, real-time monitoring, AS microenvironment response, and low toxicity, stimuli-responsive nano-based drug delivery systems(NDDSs) have been a promising approach in AS treatments. Herein, we will systematically summarize the recent advances in stimuli-responsive NDDSs for AS treatment, including internal stimuli(reactive oxygen species, enzyme, shear stress, and pH) and external stimuli(light, ultrasound, and magnetism) responsive NDDSs. Besides, we will also summarize in detail the classification of stimuli-responsive NDDSs for AS, such as organic NDDSs(e.g., lipid-based and polymer-based nanomaterials), inorganic NDDSs(e.g., metal-based nanoparticles and nonmetallic nanomaterials), and composite multifunctional NDDSs. Finally, the critical challenges and prospects of this field will also be proposed and discussed. 展开更多
关键词 atherosclerosis stimuli-responsive Nano-based drug delivery systems Theranostics Target therapy
原文传递
Intracranial Atherosclerosis: The Natural History and Management Strategies 被引量:2
6
作者 Ossama Mansour Martin Schumacher +1 位作者 Mohammad A. Farrag Foad Abd-Allah 《World Journal of Cardiovascular Diseases》 2014年第7期350-360,共11页
Intracranial atherosclerotic disease (ICAD) represents a major cause of stroke and transient ischemic attacks. The prevalence and natural course of ICAD are closely related to race and ethnicity. The best treatment fo... Intracranial atherosclerotic disease (ICAD) represents a major cause of stroke and transient ischemic attacks. The prevalence and natural course of ICAD are closely related to race and ethnicity. The best treatment for ICAD is a crucial issue;data from recent trials indicate that aggressive medical management and life style modifications are better than endovascular treatments for prevention of recurrent stroke in high-risk patients with ICAD. Endovascular treatment is still an option for subgroup of patients who are not responded to optimal medical therapy. 展开更多
关键词 INTRACRANIAL atherosclerosis MEDICAL therapy ENDOVASCULAR Treatment
暂未订购
Extracranial Carotid Atherosclerosis and Acute Ischemic Stroke in a Tertiary Hospital in Burkina Faso 被引量:1
7
作者 Alfred Anselme Dabilgou Alassane Dravé +3 位作者 Julie Marie Adeline Kyelem Hassan Koanda Christian Napon Jean Kaboré 《World Journal of Neuroscience》 2019年第2期39-51,共13页
Objective: To determine the prevalence and risk factors of carotid atherosclerosis among ischemic stroke patients in a tertiary hospital in Burkina Faso. Methodology: This was a descriptive and analytical retrospectiv... Objective: To determine the prevalence and risk factors of carotid atherosclerosis among ischemic stroke patients in a tertiary hospital in Burkina Faso. Methodology: This was a descriptive and analytical retrospective study of patients admitted at neurology department of Yalgado Ouedraogo University Teaching Hospital with ischemic stroke and cerebral large vessel atherosclerosis in the period from January 1, 2012 to December 31, 2016. Results: The prevalence of extracranial carotid atherosclerosis was 23.9%. The mean age of patients was 63.5 years (Range 31 - 90 years). The study population included 65% of men and 35% of women. Hypertension was the most common vascular risk factor (75.6%). Stroke was mostly located in the anterior circulation in 23.9%. Low HDL-C was present in 52% of patients. The majority of plaque was homogeneous (85.2%). Plaque were located in carotid bulbar artery (38.5%) followed by common carotid artery (28.2%) and extracranial internal carotid artery (18.6%). According to cerebral lesion, plaque was bilateral in 45.5%, ipsilateral in 42.3% and contralateral in 12.1% of cases. Tight stenosis was found in 30.1% of patients. There was a significant link between male gender and tight stenosis (p = 0.004). Aspirin was the most antiplatelet therapy used (95.5%). Statin therapy was used in 91% of patients. The mean duration of hospitalization was 12.5 days with a mortality rate of 7.1%. Conclusions: Our study showed that extra carotid atherosclerosis was the most common cause of ischemic stroke in Burkina Faso. Man gender was most represented than women. 展开更多
关键词 ISCHEMIC Stroke EXTRACRANIAL atherosclerosis ANTIPLATELET therapy Burkina Faso
暂未订购
Advancing Atherosclerosis Management:Innovative Targeted Cell Therapy Approaches to Reverse Disease Progression and Enhance Vascular Health
8
作者 Shanmukh Reddy Terry Oroszi 《World Journal of Cardiovascular Diseases》 2025年第7期382-403,共22页
Atherosclerosis,which is defined by plaque accumulation within artery walls,is one of the leading causes of cardiovascular disease and mortality.Although they help control symptoms and slow the condition’s progressio... Atherosclerosis,which is defined by plaque accumulation within artery walls,is one of the leading causes of cardiovascular disease and mortality.Although they help control symptoms and slow the condition’s progression,traditional treatments,including medication,surgery,and lifestyle changes,do not ad dress the underlying pathophysiology.Recent innovations in targeted cell therapy,such as gene editing,stem cell therapy,and exosome-based therapies,present encouraging methods for repairing endothelium damage,lowering in-flammation,and restoring vascular health.This study examines how different therapy approaches are related,highlighting the potential of regenerative medicine to stop the progression of atherosclerosis.Despite the potential of these developments,issues such as financial constraints,regulatory obstacles,patient-specific efficacy variability,and safety concerns must be resolved.More research and technical developments are essential to incorporate these treatments into clinical practice,improve patient outcomes,and reduce the prevalence of cardiovascular disease worldwide. 展开更多
关键词 atherosclerosis Targeted Cell therapy Stem Cells Regenerative Medicine Endothelial Progenitor Cells(EPCs) Monocyte/Macrophage Modulation Vascular Repair Immune Modulation Gene therapy
暂未订购
基于“血实宜决”理论探讨动脉粥样硬化的中医药治疗
9
作者 刘鑫 于游 +2 位作者 张欢 郭鹤 于睿 《辽宁中医杂志》 北大核心 2025年第8期47-50,共4页
在全球心血管疾病患病率和死亡率不断攀升的背景下,我国心血管疾病死亡率高居榜首,给社会的经济、公共服务等方面都带来了巨大负担。大多数心血管疾病发生的潜在原因是动脉粥样硬化,其引起的心血管疾病可归属于中医“胸痹”“心痛”“... 在全球心血管疾病患病率和死亡率不断攀升的背景下,我国心血管疾病死亡率高居榜首,给社会的经济、公共服务等方面都带来了巨大负担。大多数心血管疾病发生的潜在原因是动脉粥样硬化,其引起的心血管疾病可归属于中医“胸痹”“心痛”“脉痹”“血痹”等不同病证范畴。《素问·阴阳应象大论篇》中提出的“血实宜决”理论可认为是对瘀血阻络所致病证治则的高度概括,活血化瘀类中药中的多种有效成分在抗炎、抗氧化、调节代谢通路等方面都有突出的作用,从“血实宜决”理论探讨中医药对动脉粥样硬化的干预作用对中西医结合治疗具有良好的指导意义。 展开更多
关键词 血实宜决 动脉粥样硬化 胸痹 中医药治疗
原文传递
超24小时大脑中动脉粥样硬化闭塞性急性缺血性卒中的血管内治疗
10
作者 关敏 乔宏宇 +5 位作者 杨冰 辛秀峰 黄声明 张亮 林英泽 梁洁 《西安交通大学学报(医学版)》 北大核心 2025年第6期925-929,共5页
目的探讨发病超24 h大脑中动脉粥样硬化闭塞性急性缺血性卒中(AIS)血管内治疗(EVT)的临床疗效和安全性。方法回顾性分析2020年1月至2023年6月暨南大学附属第一医院收治的大脑中动脉粥样硬化闭塞性卒中并急诊行EVT患者的资料,根据发病至... 目的探讨发病超24 h大脑中动脉粥样硬化闭塞性急性缺血性卒中(AIS)血管内治疗(EVT)的临床疗效和安全性。方法回顾性分析2020年1月至2023年6月暨南大学附属第一医院收治的大脑中动脉粥样硬化闭塞性卒中并急诊行EVT患者的资料,根据发病至穿刺时间,将患者分为EVT≤24 h组与EVT>24 h组;比较两组患者术后7 d NIHSS评分,术后90 d独立功能预后,围手术期症状性颅内出血(sICH),围手术期急性血栓形成和90 d死亡率的差异。结果共纳入161例患者,EVT≤24 h组106例,EVT>24 h组55例。两组患者术后7 d NIHSS评分均较术前降低(P<0.01),EVT≤24 h组术后7 d NIHSS评分低于EVT>24 h组(中位数:4.5 vs.7.0,P<0.05),两组患者术后90 d独立功能预后率(45.3%vs.30.9%,95%CI:0.93~3.68)、sICH率(5.7%vs.9.1%,95%CI:0.18~2.06)、支架内急性血栓形成(6.6%vs.3.6%,95%CI:0.37~9.34)和90 d死亡率(3.8%vs.1.8%,95%CI:0.23~19.42)没有统计学差异(P>0.05)。结论对发病超过24 h的大脑中动脉粥样硬化闭塞性AIS患者,急诊EVT是可行的,但尚需前瞻性研究加以证实。 展开更多
关键词 急性缺血性脑卒中(AIS) 血管内治疗(EVT) 超晚时间窗 大脑中动脉 动脉粥样硬化
暂未订购
理中通脉法针刺对动脉粥样硬化小鼠miRNA223-3p/NLRP3炎症小体的影响 被引量:1
11
作者 尹静尧 陈以国 +3 位作者 孙瑞 李迪 黄继君 成泽东 《时珍国医国药》 北大核心 2025年第4期781-787,共7页
目的观察电针对动脉粥样硬化(AS)小鼠主动脉miRNA223-3p、NLRP3、IL-1β表达的影响,探析理中通脉法针刺改善AS的效应机制。方法SPF级ApoE^(-/-)雄性小鼠30只随机分为模型组、西药组和电针组,每组10只,高脂饲料喂养8周造模,另设C57BL/6J... 目的观察电针对动脉粥样硬化(AS)小鼠主动脉miRNA223-3p、NLRP3、IL-1β表达的影响,探析理中通脉法针刺改善AS的效应机制。方法SPF级ApoE^(-/-)雄性小鼠30只随机分为模型组、西药组和电针组,每组10只,高脂饲料喂养8周造模,另设C57BL/6J小鼠10只作为空白组,普通饲料喂养。治疗11周,空白组和模型组不予干预;西药组采用阿托伐他汀钙片稀释液灌胃;电针组取特定穴位施以电针。治疗期间记录小鼠体质量变化。治疗结束后HE染色观察小鼠主动脉壁组织形态;微板法检测血脂四项变化;WB检测小鼠主动脉NLRP3、IL-1β蛋白表达;RT-qPCR检测小鼠主动脉miR⁃NA223-3p、NLRP3 mRNA表达。结果与空白组对比,模型组小鼠主动脉出现明显的AS改变,体质量增加,血脂水平异常,主动脉miRNA223-3p表达降低,NLRP3、IL-1β表达升高(P<0.01);与模型组对比,西药组和电针组小鼠AS病理表现有所改善,体质量下降,血脂水平异常有所改善,主动脉miRNA223-3p表达升高,NLRP3、IL-1β表达降低(P<0.01或P<0.05)。结论理中通脉法针刺对AS病变有明显改善作用,这可能是通过miRNA223-3p/NLRP3途径改善炎症反应实现的。 展开更多
关键词 动脉粥样硬化 电针 理中通脉 miRNA223-3p NOD样受体热蛋白结构域相关蛋白3 炎症反应
原文传递
从NLRP3炎症小体探讨动脉粥样硬化的炎症机制及中西医结合治疗策略 被引量:1
12
作者 彭泽 赵大鹏 +3 位作者 郭东浩 孙垚 吴金乔 金娟 《中国医药导报》 2025年第18期111-115,共5页
核苷酸结合寡聚化结构域样受体蛋白3(NLRP3)炎症小体作为先天免疫核心调控枢纽,通过“双信号”激活释放白细胞介素-1β、白细胞介素-18等促炎因子,驱动动脉粥样硬化(AS)进程中内皮损伤、巨噬细胞极化及斑块不稳定性。靶向抑制NLRP3通路... 核苷酸结合寡聚化结构域样受体蛋白3(NLRP3)炎症小体作为先天免疫核心调控枢纽,通过“双信号”激活释放白细胞介素-1β、白细胞介素-18等促炎因子,驱动动脉粥样硬化(AS)进程中内皮损伤、巨噬细胞极化及斑块不稳定性。靶向抑制NLRP3通路过度激活为AS治疗关键,中西医结合治疗策略在此背景下展现独特优势:西医靶向抑制剂如MCC950、CY-09、OLT1177可快速阻断炎症级联反应;中药通过“多靶点-多途径”协同作用,减轻氧化应激、抑制炎症因子产生及NLRP3信号转导,调控NLRP3炎症小体活化与焦亡,多维度干预AS进程,并降低西药副作用及耐药风险。本文阐述NLRP3激活途径及其在AS中的作用,着重探讨靶向抑制机制,提出未来挑战与研究展望,为中西医结合防治AS提供新视角。 展开更多
关键词 核苷酸结合寡聚化结构域样受体蛋白3炎症小体 动脉粥样硬化 炎症 中西医结合治疗
暂未订购
铜死亡与动脉粥样硬化的关系及其靶向治疗的研究进展
13
作者 张子路 秦合伟 《中山大学学报(医学科学版)》 北大核心 2025年第4期558-567,共10页
动脉粥样硬化(AS)是一种缓慢而复杂的疾病,涉及多种因素,包括脂质代谢紊乱、氧自由基产生、炎性细胞浸润以及局部血栓形成等。近年来铜死亡作为一种新发现的、依赖于铜离子的程序性细胞死亡方式而备受关注,其主要因过多的铜离子与硫辛... 动脉粥样硬化(AS)是一种缓慢而复杂的疾病,涉及多种因素,包括脂质代谢紊乱、氧自由基产生、炎性细胞浸润以及局部血栓形成等。近年来铜死亡作为一种新发现的、依赖于铜离子的程序性细胞死亡方式而备受关注,其主要因过多的铜离子与硫辛酰化蛋白结合导致三羧酸循环(TCA)紊乱,破坏铁硫簇蛋白,影响相关酶和蛋白的正常功能,多途径引发细胞死亡。以往研究发现,铜死亡与AS的发生发展密切相关,铜死亡可以促进氧自由基产生、通过芬顿反应引发脂质过氧化、诱导炎症反应、干扰线粒体TCA循环等,影响巨噬细胞、内皮细胞和平滑肌细胞等血管细胞功能,干扰斑块稳定性,进而加重AS病变的发生发展,因此靶向铜死亡有望成为治疗AS及预防并发症的新方向。其中靶向检测铜死亡相关基因或许可以作为诊断AS的潜在生物标志物,且部分铜死亡抑制剂可以通过靶向抑制铜死亡的发生,显著影响AS的病程进展,提示铜死亡在AS治疗中的潜在应用价值。本文系统综述了铜代谢与铜死亡的分子机制及其在AS病理过程中的作用,并归纳总结了靶向铜死亡在AS临床诊治中的相关研究进展,以期为AS的临床治疗和预防提供新思路。 展开更多
关键词 铜死亡 动脉粥样硬化 铜代谢 炎症 靶向治疗
暂未订购
肠道菌群及其代谢产物在动脉粥样硬化发展中的作用 被引量:5
14
作者 欧阳雨欣 胡密 +5 位作者 张杨恺 林惠玲 唐宛莹 彭茂 何平平 欧阳新平 《生命的化学》 2025年第1期43-54,共12页
动脉粥样硬化(atherosclerosis,AS)是一种慢性代谢性疾病,与血脂异常和炎症密切相关,但其发病机制尚未完全阐明。肠道菌群作为调节代谢的核心因素,能够产生多种代谢产物,并参与维持宿主稳态、营养物质代谢等过程。大量研究已证实肠道菌... 动脉粥样硬化(atherosclerosis,AS)是一种慢性代谢性疾病,与血脂异常和炎症密切相关,但其发病机制尚未完全阐明。肠道菌群作为调节代谢的核心因素,能够产生多种代谢产物,并参与维持宿主稳态、营养物质代谢等过程。大量研究已证实肠道菌群在AS发展中的重要作用。本文综合当前研究,强调并阐述了肠道菌群失调及其相关代谢产物与AS之间的复杂联系,并探讨了以肠道菌群为靶点的新兴治疗方法与潜在作用,以期为预防和治疗AS提供新思路。 展开更多
关键词 肠道菌群 代谢产物 动脉粥样硬化 干预治疗
原文传递
山萸肉防治心血管疾病的药效物质及作用机制研究进展
15
作者 冯庆梅 郑涵悦 +2 位作者 董亚楠 杨佳轩 武延生 《心血管康复医学杂志》 2025年第5期748-753,共6页
心血管疾病是全球最常见的死亡原因之一,西药治疗会造成一定的毒副作用。中药在防治心血管疾病方面具有多成分、多靶点的独特优势。山萸肉是药食两用中药材,具有悠久的药用历史,古籍记载及现代文献研究均表明山萸肉具有防治心血管疾病... 心血管疾病是全球最常见的死亡原因之一,西药治疗会造成一定的毒副作用。中药在防治心血管疾病方面具有多成分、多靶点的独特优势。山萸肉是药食两用中药材,具有悠久的药用历史,古籍记载及现代文献研究均表明山萸肉具有防治心血管疾病的潜力。随着对山萸肉化学成分和药理作用的深入研究,其在防治心血管疾病方面的药效物质及作用机制逐渐清晰,本文综述了近年来山萸肉防治心血管疾病的途径和靶点,同时总结了其潜在有效成分,以期为山萸肉的临床应用和中药新药研发提供理论支撑。 展开更多
关键词 心血管疾病 山茱萸 中药疗法
暂未订购
从补法探讨中医药防治动脉粥样硬化
16
作者 吴毅杰 熊国军 伍建光 《光明中医》 2025年第3期584-587,共4页
动脉粥样硬化(AS)是一种在受累动脉内膜缓慢出现粥样斑块的进行性疾病,中医药防治AS疗效确切,但多从痰、瘀、浊等有形实邪入手。此文从“正虚致积”出发,认为正气亏虚是AS形成核心因素,脏腑亏虚、功能失调是AS斑块形成的重要环节,治疗... 动脉粥样硬化(AS)是一种在受累动脉内膜缓慢出现粥样斑块的进行性疾病,中医药防治AS疗效确切,但多从痰、瘀、浊等有形实邪入手。此文从“正虚致积”出发,认为正气亏虚是AS形成核心因素,脏腑亏虚、功能失调是AS斑块形成的重要环节,治疗中应重视补法的应用,用补法恢复正气,促使气血调和,血脉运行通畅,加速脉道中的斑块消散。 展开更多
关键词 动脉粥样硬化 中医药疗法 补法
暂未订购
NLRP3炎症小体对冠心病的作用和靶向治疗研究进展
17
作者 王银超 胡青青 周亮 《首都食品与医药》 2025年第4期18-22,共5页
冠心病是由一系列复杂因素引起的病理过程,从血管内皮细胞损伤、斑块形成、斑块破裂引起急性心肌梗死、心梗后心肌缺血再灌注损伤以及心室重构,炎症反应都贯穿始终。NLRP3炎症小体是先天免疫系统的组成部分,与无菌性炎症密切相关,也参... 冠心病是由一系列复杂因素引起的病理过程,从血管内皮细胞损伤、斑块形成、斑块破裂引起急性心肌梗死、心梗后心肌缺血再灌注损伤以及心室重构,炎症反应都贯穿始终。NLRP3炎症小体是先天免疫系统的组成部分,与无菌性炎症密切相关,也参与了冠心病的发生发展。因此,NLRP3炎症小体特异性抑制剂是目前临床药物研究的潜在靶点,为治疗冠心病提供新的治疗方案。本文就NLRP3在冠心病中的不同阶段,如动脉粥样硬化、急性心肌梗死以及梗死后心室重构中的作用机制进行分析,同时对目前NLRP3炎症小体特异性抑制剂相关药物也予以讨论。 展开更多
关键词 冠心病 NLRP3炎症小体 动脉粥样硬化 急性心肌梗死 心室重构 靶向炎症治疗
暂未订购
Tailored polysaccharide entrapping metal-organic framework for RNAi therapeutics and diagnostics in atherosclerosis
18
作者 Sen Li Han Gao +8 位作者 Haoji Wang Xiaolin Zhao Da Pan Idaira Pacheco-Fernández Ming Ma Jianjun Liu Jouni Hirvonen Zehua Liu Hélder A.Santos 《Bioactive Materials》 2025年第1期376-391,共16页
Metal-organic frameworks(MOFs)hold promise as theranostic carriers for atherosclerosis.However,to further advance their therapeutic effects with higher complexity and functionality,integrating multiple components with... Metal-organic frameworks(MOFs)hold promise as theranostic carriers for atherosclerosis.However,to further advance their therapeutic effects with higher complexity and functionality,integrating multiple components with complex synthesis procedures are usually involved.Here,we reported a facile and general strategy to prepare multifunctional anti-atherosclerosis theranostic platform in a single-step manner.A custom-designed multifunctional polymer,poly(butyl methacrylate-co-methacrylic acid)branched phosphorylatedβ-glucan(PBMMA-PG),can effectively entrap different MOFs via coordination,simultaneously endow the MOF with enhanced stability,lesional macrophages selectivity and enhanced endosome escape.Sequential ex situ char-acterization and computational studies elaborated the potential mechanism.This facile post-synthetic modifi-cation granted the administered nanoparticles atherosclerotic tropism by targeting Dectin-1+macrophages,enhancing in situ MR signal intensity by 72%.Delivery of siNLRP3 effectively mitigated NLRP3 inflammasomes activation,resulting a 43%reduction of plaque area.Overall,the current study highlights a simple and general approach for fabricating a MOF-based theranostic platform towards atherosclerosis conditioning,which may also expand to other indications targeting the lesional macrophages. 展开更多
关键词 POLYSACCHARIDE Gene therapy RNAi therapeutics atherosclerosis Metal-organic framework
原文传递
针对动脉粥样硬化多细胞功能失调的纳米药物研究进展
19
作者 慕长文 武广昊 《分析科学学报》 北大核心 2025年第2期217-228,共12页
动脉粥样硬化作为一种致命的慢性心血管炎症,正在威胁着全球范围内数以亿计人类的生命。在动脉粥样硬化过程中,多种细胞功能失调共同塑造了复杂的病理环境。纳米药物作为一种全新的药物类型,其靶向性、低毒性以及高疗效为治疗此类疾病... 动脉粥样硬化作为一种致命的慢性心血管炎症,正在威胁着全球范围内数以亿计人类的生命。在动脉粥样硬化过程中,多种细胞功能失调共同塑造了复杂的病理环境。纳米药物作为一种全新的药物类型,其靶向性、低毒性以及高疗效为治疗此类疾病提供了新的方向。本文综述了动脉粥样硬化病理进程中的多细胞功能失调,包括内皮细胞活化、单核/巨噬细胞募集、平滑肌细胞活化、泡沫细胞累积与坏死核心形成、衰老细胞旁分泌效应。同时,讨论了纳米药物在动脉粥样硬化中的设计应用,即利用多种功能元件赋予纳米药物良好的靶向性、生物相容性和治疗效果,并进一步抑制单核细胞募集、降低炎症反应、抑制平滑肌表型转换、清除泡沫细胞及衰老细胞。多细胞功能失调的机制解析为动脉粥样硬化治疗提供了新靶点,基于新靶点设计的纳米药物为治疗动脉粥样硬化提供了新策略。 展开更多
关键词 动脉粥样硬化 多细胞功能失调 纳米药物 纳米元件 治疗
暂未订购
替罗非班治疗老年穿支动脉粥样硬化病患者的有效性和安全性观察
20
作者 付胜奇 朱利利 +3 位作者 胡胜洁 张津 李浩然 张思森 《中华老年心脑血管病杂志》 北大核心 2025年第5期616-620,共5页
目的探讨替罗非班治疗老年穿支动脉粥样硬化病(branch atheromatous disease,BAD)患者的有效性和安全性。方法回顾性收集2021年6月至2023年6月郑州人民医院神经内科住院的老年BAD患者215例,根据治疗方法不同分为替罗非班1组55例和对照1... 目的探讨替罗非班治疗老年穿支动脉粥样硬化病(branch atheromatous disease,BAD)患者的有效性和安全性。方法回顾性收集2021年6月至2023年6月郑州人民医院神经内科住院的老年BAD患者215例,根据治疗方法不同分为替罗非班1组55例和对照1组160例。采用倾向性评分匹配法以1?1算法进行调整,消除2组基线特征的差异,匹配后替罗非班2组53例和对照2组53例。收集治疗前和治疗后24 h及7 d时美国国立卫生研究院卒中量表(national institutes of health stroke scale,NIHSS)评分。随访90 d,采用改良的Rankin量表(modified Rankin scale,mRS)评分评估预后。结果替罗非班1组治疗后24 h和7 d时NIHSS评分及住院时间明显低于对照1组,差异有统计学意义(P<0.05,P<0.01);替罗非班2组治疗后24 h和7 d时NIHSS评分及住院时间明显低于对照2组[3(1,4)分vs 3(2,6)分、1(0,3)分vs 1(1,4)分、8(6,10)d vs 9(8,11)d,P<0.05]。替罗非班1组mRS评分≤1分比例明显高于对照1组,差异有统计学意义(P<0.01);替罗非班2组mRS评分≤1分、mRS评分≤2分比例明显高于对照2组(71.7%vs 43.4%,P=0.003;79.2%vs 60.4%,P=0.034),mRS评分≥4分比例明显低于对照2组(5.7%vs 20.8%,P=0.045)。logistic回归分析显示,在无糖尿病、不吸烟患者中,替罗非班与良好结局增加相关(OR=0.266,95%CI:0.090~0.788,P=0.017;OR=0.341,95%CI:0.107~0.931,P=0.046)。结论替罗非班治疗老年BAD患者可能有效改善临床结局,需要进一步行随机对照试验进行验证。 展开更多
关键词 替罗非班 动脉粥样硬化 双重抗血小板治疗 倾向性评分
暂未订购
上一页 1 2 80 下一页 到第
使用帮助 返回顶部